Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... and OSAKA, Japan, May 18, 2011 Cellectis ... genome customization specialist, has appointed Wako Pure Chemical ... Company,s broad portfolio of research products and services, ... Chemical Industries is a leading distributor of research ...
... SAN JOSE, Calif., May 18, 2011 Oclaro, Inc. ... optical communications and laser solutions, today announced that its ... by Pantec Biosolutions, the leading provider of epidermal medical ... Laser Epidermal System) platform. This cutting-edge new laser platform ...
... May 17, 2011 New data presented today ... moderate to severe chronic prostatitis/chronic pelvic pain syndrome ... meeting of the American Urological Association, RAPAFLO(R) also ... of life. Chronic prostatitis/chronic pelvic pain ...
Cached Biology Technology:Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan 2Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems 2Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems 3Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6
(Date:4/17/2014)... ALBUQUERQUE, N.M. A credit-card-sized anthrax detection cartridge developed ... small business makes testing safer, easier, faster and cheaper. ... causes anthrax, is commonly found in soils all over ... illness in both humans and animals. The bacteria can ... to B. anthracis may occur through skin ...
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
(Date:4/17/2014)... Clemson professor Rajendra Singh Thursday as a "Champion ... expand solar deployment in the residential, commercial and ... Professor of Electrical and Computer Engineering and director ... a local hero leading the charge across the ... solar power and driving policy changes at the ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... at the recent United Nations meeting emphasized nutrition as ... of State Hillary Clinton said a key focus is ... of Missouri nutrition experts say getting back to basics ... families and communities in many ways. As ...
... to be met is a significant increase in the use ... to grow in the future, because biomass is used in ... and various types of materials. The planning of biomass usage ... gap between what is included in countries, and regions, current ...
... Clemson University researchers recently reported finding a new class ... how cells repair damaged DNA. The finding from Cao,s ... with computational chemist Brian Dominy appeared in the Sept. ... "A new family of deamination repair enzymes in ...
Cached Biology News:Eating balanced meals, farm-fresh produce benefits families, communities, nutrition researchers say 2Better planning required if EU is to meet energy targets 2Clemson University biochemists identify new genetic code repair tool 2
Component of HyperMu™ Insertion Kit...
Request Info...
... x 2 , Maintenance ... /each , Immunizations/Boost injections x5 ... ml) x1 /each , Production bleed ... Final Bleed ~ 100 ml blood (~50 ml ...
... 500 g protein in ... mouse whole cell lysate; Abelson transformed macrophage ... as Western blotting positive control, ... and thawing should be minimized, ...
Biology Products: